NCT06579469Recruiting
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy (PROSPER)
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 28 Aug 2024
- Start date
- 20 Jan 2026
- Primary completion date
- Jan 2029
- Lead sponsor
- St. Jude Children's Research Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT06579469
What you commit to
- Study type: Observational
- Planned participants: 100
- From 20 Jan 2026 to the primary completion date, Jan 2029
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received or planned additional disease directed therapy post CAR T cell infusion.
Other illness
- Active malignancy other than the disease under study.
Other
- Planned consolidative HSCT within 3 months post CAR T cell infusion.
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
Who the study is looking for
- Participants must have received an initial systemically-administered CAR T cell infusion for an oncologic diagnosis within the last 1-3 months (+/- 14 days).
- Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT.
- Age ≤ 30 years at CAR T cell infusion.
Age in the registry: - to 30 years · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Childrens Hospital of Colorado Coordinator of this site? Confirm its status | Aurora | United States | Recruiting |
| Children's Hospital Los Angeles Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
| St. Jude Children's Research Hospital Coordinator of this site? Confirm its status | Memphis | United States | Recruiting |
| Children's Hospital of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Recruiting |
| Children's Hospital of Philadelphia Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| Primary Children's Hospital Coordinator of this site? Confirm its status | Salt Lake City | United States | Recruiting |
| Seattle Childrens Hospital Coordinator of this site? Confirm its status | Seattle | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.